CA
CLDX icon

CoreCap Advisors’s Celldex Therapeutics CLDX Stock Holding History

CoreCap Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$713 Buy
+16
New +$571 ﹤0.01% 2108
2022
Q3 		– Sell
-16
Closed – – 798
2022
Q2 		$0 Buy
+16
New +$465 ﹤0.01% 2149
2022
Q1 		– Sell
-16
Closed -$1K – 814
2021
Q4 		$1K Buy
+16
New +$697 ﹤0.01% 2075

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CoreCap Advisors's CLDX Position: Q4 2022 in Review

CoreCap Advisors opened a new position in Celldex Therapeutics (CLDX) in Q4 2022: 16 shares worth $713. The stake represents ﹤0.01% of the portfolio and ranks #2108 among its holdings. This is a return to the name: CoreCap Advisors previously reported a position in CLDX as recently as Q2 2022.

CoreCap Advisors first reported a position in CLDX in Q4 2021 and has held it in 3 quarters since. The position peaked at $1K in Q4 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • CoreCap Advisors held 16 shares of Celldex Therapeutics worth $713 as of Q4 2022.
  • Celldex Therapeutics was a new CoreCap Advisors position in Q4 2022.
  • Celldex Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q4 2022, its #2108 holding.
  • CoreCap Advisors first reported a position in Celldex Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • CoreCap Advisors's Celldex Therapeutics position peaked at $1K in Q4 2021.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on CoreCap Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.